Contact us
Oncology CRO & Drug Development Services
Medelis is a single-source provider for oncology CRO and oncology drug development services, providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Our offerings include
- Oncology clinical trial management and design, including strategic plans for regulatory approval from Phase I through NDA
- Preclinical program analysis, design, management and execution
- Preclinical program review and “gap analysis”
- Site identification, qualification, management, contracting and payment
- Investigator identification & recruitment
- Patient recruitment & accrual strategies
- Project management & monitoring of clinical studies
Learn more about our oncology CRO services »
World-Class Expertise
We specialize in oncology clinical trials, which are are usually longer and more complex than those targeting other diseases. Medelis' medical founders, team physicians and clinical trial management physicians are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the oncology clinical research community keep us close to research trends and developments. And our entire management team, project managers and CRAs all have deep oncology experience to complement their operational and technical skills.
More about our focus on oncology »
Clinical Answers Faster
Medelis has the breadth of capabilities, depth of expertise, strategic partnerships, focus and agility to deliver accurate results quickly. We create superior research designs that yield the right data the first time. And we're organized to set up trials and recruit patients with exceptional speed.
With this approach, we can deliver faster, more accurate results and help speed our clients' drugs to market.
Recent News
March 25, 2008 - Medelis today announced the launch of Peer Perspectives in Oncology, a Q&A series that brings together some of the industry’s most respected researchers to talk about the issues facing Chief Medical Officers today: Rising costs. Optimum patient accrual. Targeted therapeutics. Patient safety. FDA regulations. Efficacy. Budgets. Timelines.